Buscar en
Enfermería Clínica (English Edition)
Toda la web
Inicio Enfermería Clínica (English Edition) Improvement in the quality of life of patients with chronic spontaneous urticari...
Journal Information
Vol. 27. Issue 6.
Pages 361-368 (November - December 2017)
Download PDF
More article options
Vol. 27. Issue 6.
Pages 361-368 (November - December 2017)
Original Article
Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life
Mejora de la calidad de vida de los pacientes con urticaria crónica espontánea tratados con omalizumab en vida real
Itzíar Larrea-Baca
Corresponding author

Corresponding author.
, María Gurpegui-Resano
Servicio de Alergología, Ambulatorio Conde Oliveto, Servicio Navarro de Salud (Osasunbidea), Pamplona, Spain
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (3)
Table 1. UAS7 score system for assessing urticaria activity.
Table 2. Main traits of the SF-36 health survey.
Table 3. Means and standard deviations of scores obtained for the tools of disorder activity (VAS, UAS-7 itchiness, UAS-7 hives) and effect on QoL (CU-Q2oL and SF-36) at four moments of assessment: at the beginning of treatment, one month after, 6 months after and 12 months after.
Show moreShow less

Evaluation of the impact on the quality of life (QOL) relating to health in patients with chronic urticaria (CSU) treated with omalizumab.


Longitudinal descriptive observational study of quality of life based on18 patients with chronic urticaria ≥12 years treated with omalizumab. Changes in QOL examined at 1 month (T1), at 6 months (T6) and 12 months (T12), by: Visual Analogical Scale (UAS), specific urticaria QOL questionnaire (CU-Q2oL), general health questionnaire (SF-36) and activity of urticaria questionnaire (Score UAS7).


The most disabling symptoms for patients were: pruritus (61.1%); decrease in health and physical activity (55.5%), wheals, swelling and nervousness (50%); depression and shame of marks (38.89%); side effects to drugs (33.33%); sleepiness and tiredness (27.78%); work (22.22%); “choosing clothes and pain” 16.67% and social relations (11.11%). Statistically significant differences were observed in T1, T6 and T12. In T1, UAS −4.72 (p=0.001); CU-Q2oL −16.38 (p<0.001); SF-36 15.44 (p=0.006); UAS7 wheals −7.27 (p=0.001), UAS7 pruritus −8.72 (p=0.003). In T6, UAS −4.26 (p=0.001); CU-Q2oL −18.94 (p<0.001); SF-36 15.41 (p<0.001); UAS7 wheals −7.41 (p=0.001), UAS7 pruritus −7.11 (p=0.001). In T12 UAS −9.61 (p=0.004); CU-Q2oL −21.38 (p=0.01); SF-36 17.53 (p=0.04); UAS7 wheals −8.23 (p=0.004), UAS7 pruritus −10.69 (p=0.004).


There was a very good response in T1, which was maintained in T6 and T12. Patients with chronic urticaria treated with omalizumab presented good results with a reduction of CUE activity and improvement of their QOL.

Quality of life
Chronic spontaneous urticaria
Quality of life questionnaire

Evaluación del impacto en la calidad de vida (CdV) relacionada con la salud en los pacientes con urticaria crónica espontánea en tratamiento con omalizumab.


Estudio observacional descriptivo longitudinal de calidad de vida partiendo de 18 pacientes con urticaria crónica espontánea ≥ 12 años tratados con omalizumab. Se analizaron los cambios en la CdV al mes (T1), a los 6 (T6) y a los 12 meses (T12), mediante: escala analógica visual (EVA), cuestionario de CdV específico de urticaria (CU-Q2oL), cuestionario de salud general (SF-36) y cuestionario de actividad de urticaria (Score UAS7).


Los síntomas más condicionantes para los pacientes fueron: prurito (61,1%); disminución de la salud y actividad física (55,5%); ronchas, hinchazón y nerviosismo (50%); depresión y vergüenza de marcas (38,89%); efectos secundarios a fármacos (33,33%); sueño y cansancio (27,78%); trabajo (22,22%); «elección de ropa y dolor» 16,67% y relaciones sociales (11,11%). Se observaron diferencias estadísticamente significativas en T1, T6 y T12. En T1, EVA -4,72 (p=0,001); CU-Q2oL -16,38 (p<0,001); SF-36 15,44 (p=0,006); UAS7 ronchas -7,27 (p=0,001), UAS7 prurito -8,72 (p=0,003). En T6, EVA -4,26 (p=0,001); CU-Q2oL -18,94 (p<0,001); SF-36 15,41 (p<0,001); UAS7 ronchas -7,41 (p=0,001), UAS7 prurito -7,11 (p=0,001). En T12 EVA -9,61 (p=0,004); CU-Q2oL -21,38 (p=0,01); SF-36 17,53 (p=0,04); UAS7 ronchas -8,23 (p=0,004), UAS7 prurito -10,69 (p=0,004).


Existió muy buena respuesta en T1, que se mantuvo en T6 y T12. Los pacientes con urticaria crónica espontánea tratados con omalizumab presentaron buenos resultados con reducción de la actividad de UCE y mejora de su CdV.

Palabras clave:
Calidad de vida
Urticaria crónica espontánea
Cuestionario calidad de vida


These are the options to access the full texts of the publication Enfermería Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Enfermería Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más